SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals,
Inc., a privately held biopharmaceutical company developing
anti-inflammatory drugs, announced today that Anthera scientists and
collaborators have released data from the Varespladib (A-002) clinical and
pre-clinical programs at the Arteriosclerosis, Thrombosis, and Vascular
Biology (ATVB) Annual Conference in Atlanta, Georgia, held on April 16-18,
2008. Anthera has completed Phase II trials in Varespladib for the
treatment of coronary heart disease.
-- Effects of a Selective Secretory Phospholipase A2 Inhibitor on
Low-Density Lipoproteins in CHD Patients with Diabetes.
-- The Synergistic Inhibition of Atherogenesis in ApoE-/- Mice Between
Pravastatin and the sPLA2 Inhibitor Varespladib (A-002).
"We are pleased to see the synergistic effect of Varespladib with statins on plaque reduction, composition and stability in a well established model of atherosclerosis," said Joaquim Trias, Ph.D., Senior Vice President of Preclinical Development at Anthera Pharmaceuticals, Inc.
"Along with the Phase II PLASMA data presented at ACC earlier this year, today's announcement gives us added confidence as we move the Varespladib clinical program forward," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "These findings further support our clinical development program as we begin Phase III clinical trials in patients with acute coronary syndromes where inflammation, atherosclerosis and cholesterol levels are highly correlated with outcomes."
Anthera Pharmaceuticals is a privately-held company committed to
developing and commercializing clinical pharmaceutical products that
address unmet medical needs of patients with life-threatening, chronic and
acute inflammatory diseases and autoimmune disorders. The Company has
acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide
rights (excluding Japan) to a series of clinical and pre-clinical compounds
that inhibit the enzymatic activity of members of the phospholipase (PLA2)
family -- a group of enzymes responsible for the release of arachidonic
acid and subsequent production of leukotrienes prostacyclins and other
mediators of inflammation. These highly potent compounds inhibit novel
upstream steps in the inflammation cascade and have the potential to
address a variety of diseases. The company has also acquired exclusive and
worldwide rights to a peptide fusion protein, A-623, for the treatment of
systemic lupus erythematosus (SLE) and other autoimmune diseases from
Amgen. For more information, please visit http://www.anthera.com
INVESTOR AND MEDIA CONTACT:
|SOURCE Anthera Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved